Header graphic for print
Dangerous Drugs & Medical Devices News & Commentary on Prescription Drug & Medical Device Lawsuits

Monthly Archives: January 2014

2005 – 89% of Risperdal users found to suffer elevated prolactin levels

Posted in Risperdal

A paper published in 2005 by K. Melkersson in Journal of Clinical Psychiatry titled “Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients.” aimed to evaluate the degree to which different atypical antipsychotic drugs elevated blood levels of prolactin (the hormone responsible for breast growth and milk production) in a group… Continue Reading

2005 – Risperdal raises prolactin levels more than Haldol

Posted in Risperdal

In a 2005 report by XY Zhang et al. titled “Prolactin levels in male schizophrenic patients treated with risperidone and haloperidol: a double-blind and randomized study.” published in Psychopharmacology, researchers aimed to “compare the effect of risperidone and haloperidol on serum PRL and investigate the relationship between serum PRL levels and clinical response in patients… Continue Reading

2011 – Study Shows: 12% of DePuy ASR XL hip replacements fail by 2 years

Posted in DePuy Hip Replacement

In 2011, a paper titled “Early failure of articular surface replacement XL total hip arthroplasty.” in The Journal of Arthroplasty by GD Steele et al., stated “The ASR (articular surface replacement) XL (DePuy, Warsaw, Ind) metal-on-metal hip arthroplasty offers the advantage of stability and increased motion. However, an alarming number of early failures prompted the… Continue Reading

“Out of joint: The story of the ASR” – British Medical Journal

Posted in DePuy Hip Replacement

In 2011, Deborah Cohen, investigations editor for the British Medical Journal wrote a piece called “Out of joint: The story of the ASR,” which chronicles the ill-fated history of the DePuy ASR metal-on-metal hip replacement systems.  Illuminating the depth and breadth of lack of concern for patient well-being at DePuy, I encourage you to read… Continue Reading

2011 – More research associates pseudotumors with metal-on-metal hip replacements

Posted in DePuy Hip Replacement

A 2011 article by YM Kwon et al. titled “‘Asymptomatic pseudotumors after metal-on-metal hip resurfacing arthroplasty: prevalence and metal ion study.” published in The Journal of Arthroplasty cites that “Symptomatic abnormal periprosthetic soft-tissue reactions (“pseudotumors”) have been reported after metal-on-metal hip resurfacing arthroplasty (MoMHRA).” Accordingly, the aims of this study were twofold: “(1) to determine… Continue Reading

2011 – Researchers link metal-on-metal hip replacements and pseudotumors

Posted in DePuy Hip Replacement

In a 2011 article by NP Hailer et al. titled “Elevation of circulating HLA DR(+) CD8(+) T-cells and correlation with chromium and cobalt concentrations 6 years after metal-on-metal hip arthroplasty.” published in the medical journal Acta Orthopaedica, researchers state “Following metal-on-metal hip arthroplasty (THA), immunological reactions including changes in lymphocyte populations, aseptic loosening, and lymphocytic… Continue Reading

FDA: Xarelto not to be approved for acute coronary syndrome

Posted in Drug Studies, FDA Regulation, Public Health

Yesterday (1/16/2014) Reuters reported that an FDA advisory panel rejected a call by Johnson and Johnson to approve their anticoagulant Xarelto (rivaroxaban) for acute coronary syndrome by a vote of 10-0 with one abstention. While Xarelto “is already used to treat and prevent deep vein thrombosis and pulmonary embolisms and to reduce the risk of… Continue Reading

Largest Monthly Drop in Prescription Drug Cost Seen in Decades

Posted in Public Health

Recent reports from MarketWatch and Bloomberg Businessweek cite that the US drug prices fell by about 1% last month, representing the largest such dip in prices in decades. Interestingly, MarketWatch reported that the cost of drugs fell by 0.9%, and that this was the biggest monthly drop since 1969, and Bloomberg reported the cost fell… Continue Reading

2011 – Study Shows: “Cup inclination, version angles” influence metal ion levels in metal-on-metal hip replacement

Posted in DePuy Hip Replacement

In a 2011 report by AJ Hart et al. published in Clinical Orthopaedics and Related Research, researchers write “Many factors affect the blood metal ion levels after metal-on-metal (MOM) hip arthroplasty” and “The main surgically adjustable variable is the amount of coverage of the head provided by the cup which is a function of the… Continue Reading

2006 – Canadian Research Team “Concerned” With Metal-on-Metal Hip Use

Posted in DePuy Hip Replacement

In 2006, the government-mandated Canadian organization Health Quality Ontario published the results of a study in Ontario Health Technology Assessment Series that aimed to “assess the safety and effectiveness of metal on metal (MOM) hip resurfacing arthroplasty for young patients compared with that of total hip replacement (THR) in the same population.” This study, titled… Continue Reading

2007 – Research shows LAP-BAND reoperation required at triple the rate stated in Warning Label

Posted in Allergan LAP-BAND

We are no longer accepting cases regarding these products.  Due to a terrible Supreme Court ruling, consumers injured by this product are no longer permitted to sue the manufacturers of this device.  We wish we could help, but the Supreme Court has taken the rights of citizens away to protect the profits of medical device… Continue Reading

2008 – LAP-BAND associated with high complication rates

Posted in Allergan LAP-BAND

We are no longer accepting cases regarding these products.  Due to a terrible Supreme Court ruling, consumers injured by this product are no longer permitted to sue the manufacturers of this device.  We wish we could help, but the Supreme Court has taken the rights of citizens away to protect the profits of medical device… Continue Reading

1999 – LAP-BAND Complications Include Perforations of Stomach, Prolapse of Stomach Through Band

Posted in Allergan LAP-BAND

We are no longer accepting cases regarding these products.  Due to a terrible Supreme Court ruling, consumers injured by this product are no longer permitted to sue the manufacturers of this device.  We wish we could help, but the Supreme Court has taken the rights of citizens away to protect the profits of medical device… Continue Reading

2009 – Risperdal shown to lower testosterone, raise prolactin – leading to male breast growth

Posted in Risperdal

In 2009, a study on the effects two antipsychotic medications – risperidone (Risperdal) and olanzapine had on sex hormone levels was published in Psychoneuroendocrinology. For years, many studies have been published connecting Risperdal and elevated prolactin levels (the hormone responsible for breast growth and milk production), demonstrating that Risperdal may lead to gynecomastia – male… Continue Reading

2000 – Risperdal raises levels of hormone responsible for male breast growth more than other similar drugs

Posted in Risperdal

According to an article published in the September 2000 edition of Clinical Therapeutics, risperidone (Risperdal) raised prolactin levels significantly more than two other common antipsychotic drugs tested, olanzapine and haloperidol. This is important because elevated prolactin levels can lead to gynecomastia – the development of breasts in males, a condition which can be very traumatizing,… Continue Reading

2003 – Study shows Risperdal causes more hyperprolactinemia than other antipsychotics

Posted in Risperdal

A 2003 report by BJ Kinon et al. published in Psychoneuroendocrinology reports that risperidone (Risperdal) leads to elevated prolactin levels at a much greater rate than other antipsychotics. Hyperprolactinemia, a condition characterized by elevated levels of prolactin – the hormone responsible for breast growth and milk production, carries with it a number of negative side… Continue Reading

2004 – Study links Risperdal and Male Breast Growth

Posted in Risperdal

In 2004, P.M. Haddad et al. published a report in the medical journal Drugs titled “Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.”  Aiming to elucidate the biochemical mechanism by which certain antipsychotic medications cause hyperprolactinemia (elevated blood levels of prolactin, the hormone responsible for breast development and milk production), the abstract to the article begins… Continue Reading

2007 – Study Links Risperdal and Male Breast Growth

Posted in Risperdal

A 2007 Journal of Clinical Psychopharmacology article titled “Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives.” provides valuable insight into complications and side-effects related to the use of certain “atypical” antipsychotic medications, specifically into those related to risperidone (Risperdal® – Janssen Pharmaceuticals, Inc.). One… Continue Reading

2004 – 19% of LAP-BAND Patients Suffer Complications

Posted in Allergan LAP-BAND

We are no longer accepting cases regarding these products.  Due to a terrible Supreme Court ruling, consumers injured by this product are no longer permitted to sue the manufacturers of this device.  We wish we could help, but the Supreme Court has taken the rights of citizens away to protect the profits of medical device… Continue Reading